References
- Abd El-Aziz, T. M., & Stockand, J. D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infection, Genetics and Evolution : journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 83, 104327 https://doi.org/https://doi.org/10.1016/j.meegid.2020.104327
- Abel, R., Salam, N. K., Shelley, J., Farid, R., Friesner, R. A., & Sherman, W. (2011). Contribution of explicit solvent effects to the binding affinity of small-molecule inhibitors in blood coagulation factor serine proteases. Chemmedchem., 6(6), 1049–1066. https://doi.org/https://doi.org/10.1002/cmdc.201000533
- Agbowuro, A. A., Huston, W. M., Gamble, A. B., & Tyndall, J. D. A. (2018). Proteases and protease inhibitors in infectious diseases. Med Res Rev, 38(4), 1295–1331. https://doi.org/https://doi.org/10.1002/med.21475
- Al-Kassmy, J., Pedersen, J., & Kobinger, G. (2020). Vaccine candidates against coronavirus infections. Where does COVID-19 stand? Viruses, 12(8), 861. https://doi.org/https://doi.org/10.3390/v12080861
- Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003). Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science (New York, N.Y.), 300(5626), 1763–1767. https://doi.org/https://doi.org/10.1126/science.1085658
- Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688. https://doi.org/https://doi.org/10.1002/jcc.20290
- Chen, H., Zhang, Z., Wang, L., Huang, Z., Gong, F., Li, X., Chen, Y., & Wu, J. J. (2020). First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients. medRxiv: 2020.2003.2022.20034041.
- Chen, J., Xia, L., Liu, L., Xu, Q., Ling, Y., Huang, D., Huang, W., Song, S., Xu, S., Shen, Y., & Lu, H. (2020). Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infectious Diseases, 7(7), ofaa241 https://doi.org/https://doi.org/10.1093/ofid/ofaa241
- Elfiky, A. A. (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, 248, 117477 https://doi.org/https://doi.org/10.1016/j.lfs.2020.117477
- Felgenhauer, U., Schoen, A., Gad, H. H., Hartmann, R., Schaubmar, A. R., Failing, K., Drosten, C., & Weber, F. (2020). Inhibition of SARS-CoV-2 by type I and type III interferons. Journal of Biological Chemistry. 295(41), 13958-13964. https://doi.org/https://doi.org/10.1074/jbc.ac120.013788
- Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/https://doi.org/10.1021/jm051256o
- Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., Song, H., Shi, Y., Li, X., Tan, W., Qi, J., & Gao, G. F. (2020). Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications, 11(1), 4417 https://doi.org/https://doi.org/10.1038/s41467-020-18233-x
- Ghosh, A. K., Xi, K., Grum-Tokars, V., Xu, X., Ratia, K., Fu, W., Houser, K. V., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2007). Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett, 17(21), 5876–5880. https://doi.org/https://doi.org/10.1016/j.bmcl.2007.08.031
- Ghosh, A. K., Xi, K., Ratia, K., Santarsiero, B. D., Fu, W., Harcourt, B. H., Rota, P. A., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2005). Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. Journal of Medicinal Chemistry, 48(22), 6767–6771. https://doi.org/https://doi.org/10.1021/jm050548m
- Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Krilov, G., Jorgensen, W. L., Abel, R., & Friesner, R. A. (2016). OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, 12(1), 281–296. https://doi.org/https://doi.org/10.1021/acs.jctc.5b00864
- Harrach, M. F., & Drossel, B. (2014). Structure and dynamics of TIP3P, TIP4P, and TIP5P water near smooth and atomistic walls of different hydroaffinity. Journal of Chemical Physics., 140(17), 174501. https://doi.org/https://doi.org/10.1063/1.4872239
- Huggins, D. J. (2020). Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. Journal of Molecular Graphics & Modelling, 100, 107710 https://doi.org/https://doi.org/10.1016/j.jmgm.2020.107710
- Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., & Ivachtchenko, A. V. (2020). AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/https://doi.org/10.1093/cid/ciaa1176
- Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289–293. https://doi.org/https://doi.org/10.1038/s41586-020-2223-y
- Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., Zhu, Y., Zhu, C., Hu, T., Du, X., Duan, Y., Yu, J., Yang, X., Yang, X., Yang, K., Liu, X., Guddat, L. W., Xiao, G., Zhang, L., Yang, H., & Rao, Z. (2020). Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol, 27(6), 529–532. https://doi.org/https://doi.org/10.1038/s41594-020-0440-6
- Kumar, V., Shin, J. S., Shie, J. J., Ku, K. B., Kim, C., Go, Y. Y., Huang, K. F., Kim, M., & Liang, P. H. (2017). Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Research, 141, 101–106. https://doi.org/https://doi.org/10.1016/j.antiviral.2017.02.007
- Kumar, V., Tan, K. P., Wang, Y. M., Lin, S. W., & Liang, P. H. (2016). Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorganic & Medicinal Chemistry, 24(13), 3035–3042. https://doi.org/https://doi.org/10.1016/j.bmc.2016.05.013
- Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020). Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nature Communications, 11(1), 2070 https://doi.org/https://doi.org/10.1038/s41467-020-16048-4
- Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 19(3), 149–150. https://doi.org/https://doi.org/10.1038/d41573-020-00016-0
- Li, Y., Xie, Z., Lin, W., Cai, W., Wen, C., Guan, Y., Mo, X., Wang, J., Wang, Y., Peng, P., Chen, X., Hong, W., Xiao, G., Liu, J., Zhang, L., Hu, F., Li, F., Zhang, F., Deng, X., & Li, L. (2020). Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med (N Y), 1(1), 105–113.e4. https://doi.org/https://doi.org/10.1016/j.medj.2020.04.001
- Liu, K., Watanabe, E., & Kokubo, H. (2017). Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. Journal of Computer-Aided Molecular Design, 31(2), 201–211. https://doi.org/https://doi.org/10.1007/s10822-016-0005-2
- Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F., Sahi, V., Figueroa, A., Guo, X. V., Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Chen, Z., Yuen, K. Y., Kwong, P. D., Sodroski, J. G., … Ho, D. D. (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 584(7821), 450–456. https://doi.org/https://doi.org/10.1038/s41586-020-2571-7
- Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., & Wang, J. (2020). Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research, 30(8), 678–692. https://doi.org/https://doi.org/10.1038/s41422-020-0356-z
- Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/https://doi.org/10.1021/acs.jctc.5b00255
- Menendez, C. A., Bylehn, F., Perez-Lemus, G. R., Alvarado, W., & de Pablo, J. J. (2020). Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Science Advances, 6(37), eabd0345. https://doi.org/https://doi.org/10.1126/sciadv.abd0345
- Nicolini, L. A., Mikulska, M., Signori, A., Di Biagio, A., Portunato, F., Vena, A., Giacomini, M., & Bassetti, M. (2020). Reply to: "Antiviral activity and safety of darunavir/cobicistat for treatment of COVID-19". Open Forum Infectious Diseases, 7(8), ofaa321.https://doi.org/https://doi.org/10.1093/ofid/ofaa321
- Paules, C. I., Marston, H. D., & Fauci, A. S. (2020). Coronavirus infections-more than just the common cold. JAMA, 323(8), 707–708. https://doi.org/https://doi.org/10.1001/jama.2020.0757
- Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/https://doi.org/10.1021/acs.jmedchem.5b00104
- Riniker, S., Barandun, L. J., Diederich, F., Kramer, O., Steffen, A., & van Gunsteren, W. F. (2012). Free enthalpies of replacing water molecules in protein binding pockets. Journal of Computer-Aided Molecular Design, 26(12), 1293–1309. https://doi.org/https://doi.org/10.1007/s10822-012-9620-8
- Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S., & Walker, R. C. (2013). routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. Journal of Chemical Theory and Computation, 9(9), 3878–3888. https://doi.org/https://doi.org/10.1021/ct400314y
- Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007). Epik: A software program for pK( a ) prediction and protonation state generation for drug-like molecules. Journal of Computer-Aided Molecular Design, 21(12), 681–691. https://doi.org/https://doi.org/10.1007/s10822-007-9133-z
- Shivanyuk, A., Ryabukhin, S., Tolmachev, A., Bogolyubsky, A., Mykytenko, D., Chupryna, A., Heilman, W., & Kostyuk, A. (2007). Enamine real database: Making chemical diversity real. Chemistry Today, 25, 58–59.
- Shu, T., Huang, M., Wu, D., Ren, Y., Zhang, X., Han, Y., Mu, J., Wang, R., Qiu, Y., Zhang, D. Y., & Zhou, X. (2020). SARS-coronavirus-2 Nsp13 Possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virologica Sinica, 35(3), 321–329. https://doi.org/https://doi.org/10.1007/s12250-020-00242-1
- Smolders, E. J., Te Brake, L. H., & Burger, D. M. (2020). SARS-CoV-2 and HIV protease inhibitors: Why lopinavir/ritonavir will not work for COVID-19 infection. Antiviral Therapy, https://doi.org/https://doi.org/10.3851/IMP3365
- Sterling, T., & Irwin, J. J. (2015). ZINC 15-ligand discovery for everyone. Journal of Chemical Information and Modeling, 55(11), 2324–2337. https://doi.org/https://doi.org/10.1021/acs.jcim.5b00559
- Ullrich, S., & Nitsche, C. (2020). The SARS-CoV-2 main protease as drug target. Bioorganic & Medicinal Chemistry Letters, 30(17), 127377 https://doi.org/https://doi.org/10.1016/j.bmcl.2020.127377
- Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/https://doi.org/10.1002/jcc.20035
- WHO (2020). Coronavirus disease 2019 (COVID-19): weekly epidemiological update. Report no. Geneva. https://apps.who.int/iris/handle/10665/334188
- Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/https://doi.org/10.1038/s41586-020-2008-3
- Yin, W., Mao, C., Luan, X., Shen, D. D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., Chang, S., Xie, Y. C., Tian, G., Jiang, H. W., Tao, S. C., Shen, J., Jiang, Y., Jiang, H., Xu, Y., … Xu, H. E. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science (New York, N.Y.), 368(6498), 1499–1504. https://doi.org/https://doi.org/10.1126/science.abc1560
- Yuen, C. K., Lam, J. Y., Wong, W. M., Mak, L. F., Wang, X., Chu, H., Cai, J. P., Jin, D. Y., To, K. K., Chan, J. F., Yuen, K. Y., & Kok, K. H. (2020). SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerging Microbes & Infections, 9(1), 1418–1428. https://doi.org/https://doi.org/10.1080/22221751.2020.1780953
- Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., von Brunn, A., Leyssen, P., Lanko, K., Neyts, J., de Wilde, A., Snijder, E. J., Liu, H., & Hilgenfeld, R. (2020). α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment. Journal of Medicinal Chemistry, 63(9), 4562–4578. https://doi.org/https://doi.org/10.1021/acs.jmedchem.9b01828
- Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science (New York, N.Y.), 368(6489), 409–412. https://doi.org/https://doi.org/10.1126/science.abb3405
- Ziebuhr, J., Snijder, E. J., & Gorbalenya, A. E. (2000). Virus-encoded proteinases and proteolytic processing in the Nidovirales. The Journal of General Virology, 81(Pt 4), 853–879. https://doi.org/https://doi.org/10.1099/0022-1317-81-4-853